Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai and Biogen’s newly approved Alzheimer’s drug Leqembi (lecanemab) is looking to do what its amyloid-targeted predecessor, Biogen’s Aduhelm (aducanumab), has yet to accomplish — hit blockbuster status.
In a press conference yesterday, Eisai execs projected $7 billion (1 trillion yen) in Leqembi worldwide sales by 2030, assuming broader coverage from CMS, which has so far limited the use of any amyloid-targeted Alzheimer’s drugs to clinical trials. The $7 billion estimate is based on the company’s estimate that about 2.5 million people will be eligible for treatment by 2030, with prevalence in Asia/Latin America and China potentially reaching 70% of the global total.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.